Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Announces EU PRIME Review Status for BCMA CAR-T Candidate

publication date: Sep 24, 2019

Shanghai's CARsgen Therapeutics received PRIority MEdicine status in the EU for its anti-BCMA CAR-T cell therapy (CT053) as a treatment for relapsed or refractory multiple myeloma. In a China Phase I trial of CT053, 21 out of 24 myeloma patients (87.5%) experienced an objective response and 19 out of 24 patients (79.2%) achieved a complete response. The patients had received an average of 4.5 prior treatments. There was no cytokine release syndrome of grade 3 or higher. CARsgen will report the duration of response at a later date. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital